Corticosteroid Effects on Inflammatory Markers

Mechanism of Effect on Inflammatory Markers

The American College of Radiology suggests that corticosteroids, such as prednisone, cause rapid and substantial reductions in inflammatory markers, with the most dramatic decreases occurring within the first few weeks of treatment, although the exact duration may vary depending on the condition being treated 1, 2, 3.

The European Society for Medical Oncology recommends that when evaluating inflammatory conditions in patients on prednisone, clinicians must recognize that CRP and ESR will be artificially suppressed and may not accurately reflect true disease activity, with a strength of evidence level of high 1, 2, 3, 4, 5.
The American Society of Clinical Oncology guidelines for immune-related adverse events recommend monitoring ESR and CRP, but clinicians must be aware that these values will be lower in patients already receiving corticosteroids, with a moderate level of evidence 1, 2, 4, 5.

The American College of Radiology suggests that a "normal" CRP or ESR in a steroid-treated patient does not exclude active inflammation or infection, and alternative markers such as PCT may be more reliable, with a low level of evidence 6, 7.

The Annals of Oncology reports that the suppressive effect on inflammatory markers is dose-dependent and rapid, with moderate doses (10-20 mg prednisone daily) sufficient to significantly reduce CRP and ESR, although the optimal dose may vary depending on the individual patient and condition being treated, with a high level of evidence 1, 2, 8.

The Journal for ImmunoTherapy of Cancer and Gastroenterology suggest that if CRP or ESR are elevated in a patient taking prednisone, this suggests either inadequate steroid dosing for the underlying inflammatory condition OR a concurrent acute process that is overwhelming the anti-inflammatory effects of the corticosteroid, with a moderate level of evidence 3, 9.